Dr. Jian Zheng 郑建
Chief Physician
Department of Medical Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized and individualized precision treatment for lung cancer and lymphoma, including chemotherapy, targeted therapy, endocrine therapy, and interpretation of high-throughput gene sequencing reports.
Dr. Zheng is skilled in diagnosis and treatment strategies for common tumors and emergency care for critical patients. Expertise includes precision oncology, such as chemotherapy, molecular targeted therapy, endocrine therapy, and application of high-throughput gene sequencing reports. Psychological therapy is integrated into daily clinical practice.
Professional roles
- Member, Youth Council, China Anti-Cancer Association
- Member, Tumor Nutrition Professional Committee, China Anti-Aging Promotion Association
- Member, Lung Cancer Group, Molecular Diagnostic Medicine Professional Committee, Chinese Research Hospital Association
- Member, Immunotherapy Adverse Reaction Management Professional Committee, Beijing Cancer Prevention and Treatment Society
Name order: in Chinese the family name comes first (Zheng Jian). Papers usually list the name as Jian Zheng or Zheng J.
Selected publications
15 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Breast Care (Basel), 2022 (first author): Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma. PubMed 35355703
- Cancer Manag Res, 2021 (first author): MicroRNA-32 and MicroRNA-548a Promote the Drug Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting ROBO1 and Inhibiting the Activation of Wnt/β-Catenin Axis. PubMed 33854371
- Expert Rev Clin Pharmacol, 2016 (first author): Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients. PubMed 27494194
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2016 (first author): [Analysis of Clinical Prognosis of 50 Cases of Primary Gastrointestinal Non-Hodgkin's Lymphoma]. PubMed 27531773
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion